Reunion Neuroscience Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2 study of RE104, a novel serotonergic psychedelic compound, for the treatment of postpartum depression (PPD). The Phase 2 study, the RECONNECT Trial, is a multicenter, randomized, double-blind, parallel-group, active-dose placebo-controlled study, which will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. The study is expected to begin in fourth quarter 2023 with a targeted data readout in late 2024.
1st Jan change | Capi. | |
---|---|---|
+31.81% | 59TCr | |
-3.42% | 36TCr | |
+18.02% | 33TCr | |
+4.27% | 29TCr | |
+15.23% | 24TCr | |
+9.93% | 21TCr | |
-7.20% | 20TCr | |
+8.12% | 17TCr | |
-1.42% | 16TCr |